Wednesday, November 25, 2015

Phila. small pharma gets busy to start 2012

Echo Therapeutics raised $3.6 million after investors exercised warrants, while ViroPharma and Inovio both made leadership moves.

Phila. small pharma gets busy to start 2012

Think many people found a car under their Christmas trees? (Elizabeth Robertson / Staff Photographer)
Think many people found a car under their Christmas trees? (Elizabeth Robertson / Staff Photographer) INQUIRER ROBERTSON

As we await Friday's jobs report, there are some leaves to scoop out of your tea today. The Commerce Department releases its November data on factory orders at 10 a.m.

But I'm more interested in what the automakers will say about December auto sales. Think many people found a Lexus or Dodge Dart under their Christmas trees?

Some bustle at the start of the year among the region's smaller life-sciences firms. Philadelphia-based Echo Therapeutics said that it received cash proceeds of $3.6 million following exercises of warrants. Echo has been working on a glucose monitoring system for diabetics. It said its year-end cash balance was $9.2 million.

In some people-related news, the No. 2 exec at Chadds Ford-based Endo Pharmaceuticals has been named to the board of Exton-based ViroPharma. Julie McHugh, Endo's chief operating officer since March 2010, joins the eight-member board of the biopharmaceutical company that had $399 million in sales for the nine-month period ended Sept. 30.

And Blue Bell-based Inovio Pharmaceuticals promoted Niranjan Sardesai to chief operating officer from senior vice president of research and development. Inovio, which is developing synthetic vaccines, also said that its senior vice president of business development, Kevin Rassas, is retiring.

Inquirer Columnist
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at

Mike Armstrong Inquirer Columnist
Also on
letter icon Newsletter